The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
The impact of ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study
Abstract
Classical antipsychotics like haloperidol are suggested to increase oxidative stress and oxidative cell injury in the brain. Pro-oxidant effect of haloperidol may influence the course and treatment outcomes of schizophrenia. Dietary supplementation of either antioxidants or omega-3 fatty acids was found to improve symptoms of schizophrenia. Thus we decided to assess the impact of combining omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol. Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day. Patients were assessed with Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Simpson Angus Scale (SAS) and Barnes Akathisia Rating Scale (BARS) over a 4 month period. Gluthatione peroxidase, superoxide dismutase, malondialdehyde, vitamin E and C levels were also evaluated at baseline and at the end of study. BPRS, SANS, SAS and BARS scores obtained at follow-up visits were significantly lower compared to baseline. Superoxide dismutase level was significantly lower at the end of study. No significant differences were detected in other laboratory parameters. Our results support the beneficial effect of the supplementation on positive and negative symptoms of schizophrenia as well as the severity of side effects induced by haloperidol. The effect of supplementation on akathisia is especially noteworthy and it has not been investigated in previous studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other studies reported that supplementation of patients with schizophrenia with vitamins C and E and omega-3 fatty acids provided positive results in terms of extrapyramidal side effects (Sivrioglu et al. 2007).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Sivrioglu et al. 2007
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
[1] Role of free radicals and catalytic metal ions in human disease: An overview
Halliwell, B., & Gutteridge, J. M. C. (1990) · Methods in Enzymology · doi:10.1016/0076-6879(90)86093-b · Cited by 4,994
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
Tietz Textbook of Clinical Chemistry
(1999) · Archives of Pathology & Laboratory Medicine · doi:10.5858/123.7.646b · Cited by 2,518
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
Tietz Textbook of Clinical Chemistry
David (1994) · JAMA · doi:10.1001/jama.1994.03520080086056 · Cited by 707
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329
Flagged first, then by citations
3 of the 37 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Berger, 2004, Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis: a double-blind randomised placebo-controlled add on study in 80 drug-naive first episode psychosis patients [abstract], Int J Neuropsychopharmacol, 7, s422
- Mahadik, 1997, Essential fatty acids in the treatment of schizophrenia, Drugs Today, 33, 5
Cited by
Sorted by citations
Items 101–102 of 102
Suresh, G., Chengaiyan, J. G., Dabaghzadeh, F., & Ahmad, F. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1965059
Pawełczyk, T., Pawełczyk, A. M., & Rabe‐Jabłońska, J. (2009) · Psychiatria i Psychologia Kliniczna
Metadata
- Authors
- Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E.
- Affiliations
- Bursa Uludağ Üni̇versi̇tesi̇ (TR)
- Corresponding author
- Sivrioglu, E.Y.
- ORCID
- Sarandöl, E.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 31
- Issue
- 7
- Pages
- 1493-1499
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2040401967
- Cited by
- 102
- References
- 37
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 5 · 2015: 9 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Bursa Uludag University - AVESIS (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- schizophrenia, omega-3 fatty acids, vitamin E supplementation, vitamin C supplementation, haloperidol, antipsychotic adverse effects, akathisia, oxidative stress, antioxidant supplementation, superoxide dismutase, malondialdehyde, glutathione peroxidase, negative symptoms, positive symptoms
- MeSH terms
- Adolescent, Adult, Antioxidants, Ascorbic Acid, Erythrocytes, Female, Haloperidol, Humans, Male, Malondialdehyde, Middle Aged, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Superoxide Dismutase, Antipsychotic Agents, Vitamin E, Lipid Peroxidation, Fatty Acids, Omega-3, Treatment Outcome, Akathisia, Drug-Induced
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
